Hormonersatztherapie nach Mamma- und Ovarialkarzinom

Translated title of the contribution: Hormone replacement therapy after breast and ovarian cancer

M. Thill*, D. Fischer, K. Röder, D. W. Lüdders, K. Diedrich, C. Dittmer

*Corresponding author for this work


Breast cancer patients undergoing chemotherapy or anti-endocrine treatment suffer from a subsequent lack of estrogen. While these women would benefit substantially by estrogen replacement, the pertinent data are sparse and inconsistent. Observational studies have not shown an increased risk of recurrence under hormone replacement therapy (HRT); however, the studies are heterogeneous, retrospective and mostly underpowered. The few randomized prospective studies suggest an increased recurrence rate with HRT regimens. Since ovarian cancer is a hormone-related malignancy as well, HRT in perimenopausal and postmenopausal women may have an impact on ovarian cancer risk, especially after primary treatment, but data are scanty. Epidemiological studies have shown that long-term HRT might even increase the risk of ovarian cancer The data on HRT after ovarian cancer treatment are even scantier ; thus, there are no reliable recommendations. This paper reviews the current literature concerning the feasibility of HRT in order to develop new recommendations.

Translated title of the contributionHormone replacement therapy after breast and ovarian cancer
Original languageGerman
JournalGynakologische Endokrinologie
Issue number1
Pages (from-to)35-40
Number of pages6
Publication statusPublished - 01.02.2010


Dive into the research topics of 'Hormone replacement therapy after breast and ovarian cancer'. Together they form a unique fingerprint.

Cite this